Growth hormone excess promotes breast cancer chemoresistance

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 10, 2009, Pages 3931-3938

  Zatelli, Maria Chiara ^a   Minoia, Mariella ^a   Molè, Daniela ^a   Cason, Valentina ^a   Tagliati, Federico ^a   Margutti, Angelo ^a   Bondanelli, Marta ^a   Ambrosio, Maria Rosaria ^a   Degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; DEOXYCORTICOSTERONE ACETATE; DOXORUBICIN; GROWTH HORMONE; MULTIDRUG RESISTANCE PROTEIN 1; PEGVISOMANT; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ACROMEGALY; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER MORTALITY; CANCER RESISTANCE; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; ONCOGENE C FOS; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

EID: 70349909883     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1026     Document Type: Article

References (32)

1. Kleinberg DL, Wood TL, Furth PA, Lee AV 2009 Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30:51-74
2. Perry JK, Mohankumar KM, Emerald BS, Mertani HC, Lobie PE 2008 The contribution of growth hormone to mammary neoplasia. J Mammary Gland Biol Neoplasia 13:131-145
3. Shevah O, LaronZ2007 Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res 17:54-57
4. Emerman JT, Leahy M, Gout PW, Bruchovsky N 1985 Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17:421-424 (Pubitemid 15043142)
5. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A 1993 Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A:492-1427 (Pubitemid 23036292)
6. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, PollakM1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396
7. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346-1353
8. Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pivonello R, Vitale G, Scillitani A, Attanasio R, Cecconi E, Daffara F, Gaia E, Martino E, Lombardi G, Angeli A, ColaoA2005 Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 90:84-90
9. Nabarro JDN 1987 Acromegaly. Clin Endocrinol (Oxf) 26:481-512
10. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
11. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni Jr JF 2002 Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13:395-400 (Pubitemid 34666594)
12. Jenkins PJ 2004 Acromegaly and cancer. Horm Res 62(Suppl 1): 108-115
13. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV 2006 The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 98:315-327 (Pubitemid 44195602)
14. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H 2001 Phosphatidylinositol/3-kinase/Akt-mediated activation of estrogen receptor α: a new model for anti-estrogen receptor resistance. J Biol Chem 276:9817-9824 (Pubitemid 37391881)
15. Soule HD, Vazguez J, Long A, Albert S, Brennan M 1973 A human cell line from a pleural effusion derived from a breast carcinoma. J Nat Cancer Inst 51:1409-1416
16. Levenson AS, Jordan VC 1997 MCF7: The first hormone-responsive breast cancer cell line. Cancer Res 57:3071-3078 (Pubitemid 27351713)
17. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C, Bondanelli M, degli Uberti EC 2005 Cyclooxigenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a P-gp mediated mechanism. J Clin Endocrinol Metab 90:5754-5760
18. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC 2003 Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 88:2797-2802
19. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC 2002 Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 297:828-834
20. Cui TX, Kwok R, Schwartz J 2008 Cooperative regulation of endogenous cAMP-response element binding protein and CCAAT/enhancer-binding protein β in GH-stimulated c-fos expression. J Endocrinol 196:89-100 (Pubitemid 351234574)
21. Gooch JL, Van Den Berg CL, YeeD 1999 Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56:1-10 (Pubitemid 29435810)
22. Guvakova MA, Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57:2606-2610 (Pubitemid 27283767)
23. Zatelli MC, Luchin A, Tagliati F, Leoni S, Piccin D, Bondanelli M, Rossi R, degli Uberti EC 2007 Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 14:1029-1038 (Pubitemid 351252434)
24. Kaulsay KK, Mertani HC, Lee KO, Lobie PE 2000 Autocrine human growth hormone enhancement of human mammary carcinoma cell spreading is Jak2 dependent. Endocrinology 141:1571-1584
25. Kaulsay KK, Zhu T, Bennett W, Lee KO, Lobie PE 2001 The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 142:767-777 (Pubitemid 32222426)
26. Zhu Z, Mukhina S, Zhu T, Mertani HC, Lee KO, Lobie PE 2005 p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis. Oncogene 24:3774-3785 (Pubitemid 40826876)
27. Mojarrad M, Momeny M, Mansuri F, Abdolazimi Y, Tabrizi MH, Ghaffari SH, Tavangar SM, Modarressi MH 2009 Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Med Oncol, doi: 10.1007/s12032-009- 9237-5
28. Brunet-Dunand SE, Vouyovitch C, Araneda S, Pandey V, Vidal LJ, Print C, Mertani HC, Lobie PE, Perry JK 2009 Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150:1341-1352
29. Gil-Puig C, BlancoM,García-Caballero T, Segura C, Pérez-Fernández R 2002 Pit-1/GHF-1 and GH expression in the MCF-7 human breast adenocarcinoma cell line. J Endocrinol 173:161-167 (Pubitemid 34428902)
30. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, ParkerMW,Waters MJ 2005 Model forGHreceptor activation based on subunit rotation within a constitutive dimer. Nat Struct Mol Biol 12:814-821 (Pubitemid 43086257)
31. Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ 2002 Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci USA 99:9858-9863 (Pubitemid 34831137)
32. Lichanska AM, Waters MJ 2008 Newinsights into growth hormone receptor function and clinical implications. Horm Res 69:138-145